ClinicalTrials.gg
CompletedNCT03777865Updated Apr 21, 2020Results posted

Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India

A Phase 4 interventional study of 13vPnC in Vaccines, sponsored by Pfizer. Completed at 4 sites in India. Open to participants aged 6 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-21.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Study summary

This is a Phase 4, open-label, single-arm, multicenter study in which subjects 6 to 17 years of age will receive 1 dose of 13vPnC.

Read the detailed description

A Phase 4, open-label, single-arm, multicenter study to describe the safety of 13-valent Pneumococcal Conjugate Vaccine in children 6 to 17 years of age in India.

02

Conditions studied

  • Vaccines
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Evidence of a personally signed and dated document (ICD) indicating that the subject's parent(s)/legal guardian(s) has/have been informed of all pertinent aspects of the study.

    Note: The subject's assent may also be required depending on local requirements.

  2. Healthy male or female children 6 to 17 years of age at the time of vaccination.
  3. Parent(s)/legal guardian(s)/child willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  4. Male subject not able to father children, male subject who is able to father children and willing to use a highly effective method of , female subject not of , or female subject of childbearing potential and at risk for pregnancy who is willing to use a highly effective method of contraception.

Note: Female subjects of childbearing potential are defined as female subjects 9 years old or have experienced menarche, whichever is earlier, and who are anatomically and functionally able to conceive.

Exclusion criteria

Exclusion Criteria:

  1. Child who is a family member of:

    • Investigator site staff members directly involved in the conduct of the study;
    • Site staff members otherwise supervised by the investigator;
    • Pfizer employees directly involved in the conduct of the study.
  2. Participation in other studies involving drug(s) within 28 days prior to study entry and/or during study participation. Participation in observational studies is permitted.
  3. History of severe adverse reaction, including such as anaphylaxis, associated with a vaccine or vaccine component.
  4. to vaccination with pneumococcal conjugate vaccines (refer to local package insert).
  5. Previous vaccination with licensed or investigational pneumococcal vaccine.
  6. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  7. History of culture-proven invasive disease caused by S pneumoniae.
  8. Major known congenital malformation or serious chronic disorder.
  9. Known or suspected immune deficiency or suppression.
  10. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  11. Pregnant females; breastfeeding females; fertile males and females of who are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    13vPnC provided as a 0.5-mL dose in a prefilled syringe

    All subjects receive a single dose (0.5mL) of 13vPnC

    Biological: 13vPnC

Interventions

  • Biological13vPnC

    All subjects receive a single dose (0.5mL) of 13vPnC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Local Reactions by Severity Within 7 Days After Vaccination

    Local reactions (redness, swelling and pain \[tenderness\]) at the 13vPnC injection site were monitored daily for 7 days after vaccination. Redness and swelling were measured and recorded in a measuring device units. 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as; any (any redness or swelling at the injection site), mild (1 to 4 measuring device units = 0.5 to 2.0 cm), moderate (5 to 14 measuring device units = 2.5 to 7.0 cm) and severe (greater than \[\>\]14 measuring device units = \>7.0 cm). Pain (tenderness) at injection site was categorized as; any: any pain at the injection site, mild: did not interfere with activity, moderate: interfered with activity and severe: prevented daily activity.

    Time frame: Within 7 days after vaccination on Day 1 (up to Day 7)

  2. Percentage of Participants Reporting Systemic Events by Severity Within 7 Days After Vaccination

    Systemic events included fever, fatigue(tiredness), headache, muscle pain, joint pain, vomiting and diarrhea. Fever: greater than or equal to (\>=) 38.0 degrees Celsius (C), \>=38.0 degrees C to \<=38.4 degrees C, \>=38.5 to \<=38.9 degrees C, 39.0 to 40.0 degrees C, \> 40.0 degrees C. Fatigue, headache, muscle pain and joint pain graded as any (any fatigue, headache, muscle pain, joint pain), mild(did not interfere with activity), moderate(some interference with activity) or severe(prevented daily routine activity). Vomiting was graded as any (any vomiting), mild (1-2 times in 24 hours \[hrs.\]), moderate(\>2 times in 24 hrs.) or severe (required intravenous hydration). Diarrhea was graded as any(any diarrhea), mild (2-3 loose stools in 24 hrs.), moderate(4-5 loose stools in 24 hrs.) or severe(\>=6 loose stools in 24 hrs.)

    Time frame: Within 7 days after vaccination on Day 1 (up to Day 7)

  3. Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. Treatment-emergent were events between first dose of study drug and up to 1 month that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.

    Time frame: up to 1 month after vaccination on Day 1

07

Results

Posted Apr 21, 2020

Participant flow

Participant flow — Overall Study
Milestone13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
Started100
Completed100
Not completed0

Outcome measures

PrimaryPercentage of Participants Reporting Local Reactions by Severity Within 7 Days After Vaccination

Local reactions (redness, swelling and pain \[tenderness\]) at the 13vPnC injection site were monitored daily for 7 days after vaccination. Redness and swelling were measured and recorded in a measuring device units. 1 measuring device unit=0.5 centimeter (cm). Redness and swelling were graded as; any (any redness or swelling at the injection site), mild (1 to 4 measuring device units = 0.5 to 2.0 cm), moderate (5 to 14 measuring device units = 2.5 to 7.0 cm) and severe (greater than \[\>\]14 measuring device units = \>7.0 cm). Pain (tenderness) at injection site was categorized as; any: any pain at the injection site, mild: did not interfere with activity, moderate: interfered with activity and severe: prevented daily activity.

Time frame:
Within 7 days after vaccination on Day 1 (up to Day 7)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Local Reactions by Severity Within 7 Days After Vaccination
percentage of participants13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
Redness: Any14.9 (7.7 to 25.0)
Redness: Mild14.9 (7.7 to 25.0)
Redness: Moderate0 (0.0 to 4.9)
Redness: Severe0 (0.0 to 4.9)
Swelling: Any17.6 (9.7 to 28.2)
Swelling: Mild17.6 (9.7 to 28.2)
Swelling: Moderate0 (0.0 to 4.9)
Swelling: Severe0 (0.0 to 4.9)
Pain: Any67.0 (56.4 to 76.5)
Pain: Mild45.1 (34.6 to 55.8)
Pain: Moderate19.8 (12.2 to 29.4)
Pain: Severe2.2 (0.3 to 7.7)
PrimaryPercentage of Participants Reporting Systemic Events by Severity Within 7 Days After Vaccination

Systemic events included fever, fatigue(tiredness), headache, muscle pain, joint pain, vomiting and diarrhea. Fever: greater than or equal to (\>=) 38.0 degrees Celsius (C), \>=38.0 degrees C to \<=38.4 degrees C, \>=38.5 to \<=38.9 degrees C, 39.0 to 40.0 degrees C, \> 40.0 degrees C. Fatigue, headache, muscle pain and joint pain graded as any (any fatigue, headache, muscle pain, joint pain), mild(did not interfere with activity), moderate(some interference with activity) or severe(prevented daily routine activity). Vomiting was graded as any (any vomiting), mild (1-2 times in 24 hours \[hrs.\]), moderate(\>2 times in 24 hrs.) or severe (required intravenous hydration). Diarrhea was graded as any(any diarrhea), mild (2-3 loose stools in 24 hrs.), moderate(4-5 loose stools in 24 hrs.) or severe(\>=6 loose stools in 24 hrs.)

Time frame:
Within 7 days after vaccination on Day 1 (up to Day 7)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events by Severity Within 7 Days After Vaccination
percentage of participants13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
Fever: >=38 degrees C4.1 (0.9 to 11.5)
Fever: >=38 degrees C to <=38.4 degrees C1.4 (0.0 to 7.4)
Fever:>=38.5 degrees C to <=38.9 degrees C2.7 (0.3 to 9.5)
Fever:>=39.0 degrees C to <=40.0 degrees C0 (0.0 to 4.9)
Fever: >40.0 degrees C0 (0.0 to 4.9)
Fatigue: Any31.2 (21.1 to 42.7)
Fatigue: Mild22.1 (13.4 to 33.0)
Fatigue: Moderate6.5 (2.1 to 14.5)
Fatigue: Severe2.6 (0.3 to 9.1)
Headache: Any25.0 (15.8 to 36.3)
Headache: Mild15.8 (8.4 to 26.0)
Headache: Moderate6.6 (2.2 to 14.7)
Headache: Severe2.6 (0.3 to 9.2)
Muscle pain: Any27.3 (17.7 to 38.6)
Muscle pain: Mild20.8 (12.4 to 31.5)
Muscle pain: Moderate3.9 (0.8 to 11.0)
Muscle pain: Severe2.6 (0.3 to 9.1)
Joint pain: Any13.0 (6.4 to 22.6)
Joint pain: Mild3.9 (0.8 to 11.0)
Joint pain: Moderate7.8 (2.9 to 16.2)
Joint pain: Severe1.3 (0.0 to 7.0)
Vomiting: Any9.6 (3.9 to 18.8)
Vomiting: Mild8.2 (3.1 to 17.0)
Vomiting: Moderate1.4 (0.0 to 7.4)
Vomiting: Severe0 (0.0 to 4.9)
Diarrhea: Any4.1 (0.9 to 11.5)
Diarrhea: Mild2.7 (0.3 to 9.5)
Diarrhea: Moderate1.4 (0.0 to 7.4)
Diarrhea: Severe0 (0.0 to 4.9)
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event. Treatment-emergent were events between first dose of study drug and up to 1 month that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.

Time frame:
up to 1 month after vaccination on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participants13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
AEs75.0 (65.3 to 83.1)
SAEs1.0 (0.0 to 5.4)

Adverse events

Collected over up to 1 month after vaccination on Day 1. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13-Valent Pneumococcal Conjugate (13vPnC) Vaccine0/100 (0%)1/100 (1%)75/100 (75%)
Most frequent serious events
Most frequent serious events
Event13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
Hepatitis acuteHepatobiliary disorders1/100
Most frequent other events
Showing 10 of 15
Most frequent other events
Event13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
Pain at the injection siteSkin and subcutaneous tissue disorders61/91
FatigueGeneral disorders24/77
Muscle painGeneral disorders21/77
HeadacheGeneral disorders19/76
SwellingSkin and subcutaneous tissue disorders13/74
RednessSkin and subcutaneous tissue disorders11/74
Joint painGeneral disorders10/77
VomitingGeneral disorders7/73
DiarrhoeaGeneral disorders3/73
FeverGeneral disorders3/73

Baseline characteristics

The safety population included all participants who received 1 dose of an investigational product.

Age, Continuous
Age, Continuous(years)13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
Mean10.28 ± 2.985
Sex: Female, Male
Sex: Female, Male(Participants)13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
Female47
Male53
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
Hispanic or Latino0
Not Hispanic or Latino100
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)13-Valent Pneumococcal Conjugate (13vPnC) Vaccine
American Indian or Alaska Native0
Asian100
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Manipal Hospital / Department of Pediatrics
    Bengaluru, Karnataka 560017, India
  • KEM Hospital Research Centre
    Pune, Maharashtra 411 011, India
  • Christian Medical College
    Ludhiana, Punjab 141 008, India
  • Kanchi Kamakoti CHILDS Trust Hospital
    Chennai, Tamil Nadu, 600034, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Apr 2019, 4 months.

Results were first posted in Apr 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2018
First posted
Dec 17, 2018
StartActual
Dec 14, 2018
Primary completionActual
Apr 17, 2019
CompletionActual
Apr 17, 2019
Results first posted
Apr 21, 2020
Last update
Apr 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03777865
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Dec 14, 2018
Primary completion
Apr 17, 2019
Completion
Apr 17, 2019
Results posted
Apr 21, 2020
Last update
Apr 21, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion